IP Library › Granted Patent US 12,534,508
Granted Patent B2
US 12,534,508 · App. 17/816,496 · Granted Jan 27, 2026

Anti-human papillomavirus 16 E7 T cell receptors

Inventors: Christian S. Hinrichs (Bethesda, MD); Steven A. Rosenberg (Potomac, MD)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
C07K14/7051A61K38/1774C07K16/2809G01N33/56983G01N33/57484A61K38/00C07K2319/00C07K2319/32G01N2333/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,534,508
App. No.
17/816,496
Granted
Jan 27, 2026
Kind
B2
Abstract

Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E7 11-19 . Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.

Claims (65)

1 . A method of producing an engineered population of human peripheral blood lymphocytes (PBLs), the method comprising:

introducing a recombinant expression vector to an isolated population of human PBLs, wherein the recombinant expression vector comprises a nucleotide sequence encoding a T cell receptor (TCR) comprising an alpha chain complementarity determining region (CDR) 1 amino acid sequence of SEQ ID NO: 3, an alpha chain CDR2 amino acid sequence of SEQ ID NO: 4, an alpha chain CDR3 amino acid sequence of SEQ ID NO: 5, a beta chain CDR1 amino acid sequence of SEQ ID NO: 6, a beta chain CDR2 amino acid sequence of SEQ ID NO: 7, and a beta chain CDR3 amino acid sequence of SEQ ID NO: 8, and wherein the TCR has antigenic specificity for human papillomavirus (HPV) 16 E7 11-19 .

2 . The method of claim 1 , wherein the TCR comprises the amino acid sequences of:

(a) SEQ ID NO: 9 and

(b) SEQ ID NO: 10, wherein X at position 2 is Ala or Gly.

3 . The method of claim 1 , wherein the TCR further comprises the amino acid sequences of:

(a) SEQ ID NO: 16, wherein

(i) X at position 48 is Thr or Cys;

(ii) X at position 112 is Ser, Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 114 is Met, Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp; and

(iv) X at position 115 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp; and

(b) SEQ ID NO: 18, wherein X at position 56 is Ser or Cys.

4 . The method of claim 1 , wherein the TCR further comprises the amino acid sequences of:

(a) any one of SEQ ID NOs: 14, 17, 21, 24, and 25; and

(b) any one of SEQ ID NOs: 15, 19, and 23.

5 . The method of claim 1 , wherein the TCR comprises the amino acid sequences of:

(a) (i) SEQ ID NO: 12, (ii) SEQ ID NO: 22, (iii) SEQ ID NO: 26, (iv) SEQ ID NO: 9 and 24, (v) SEQ ID NO: 9 and 16, or (vi) SEQ ID NOs: 9 and 17; and

(b) (i) SEQ ID NOs: 10 and 18 or (ii) any one of SEQ ID NOs: 13, 20, and 27.

6 . The method of claim 1 , wherein the TCR comprises a human variable region and a murine constant region.

7 . The method of claim 1 , wherein the isolated population of human PBLs is an isolated population of human CD8 + T cells.

8 . The method of claim 1 , wherein the recombinant expression vector is a viral vector.

9 . The method of claim 1 , wherein the recombinant expression vector is a retroviral vector.

10 . A method of producing an engineered population of human cells, the method comprising:

introducing a recombinant expression vector to an isolated population of human cells, wherein the recombinant expression vector comprises a nucleotide sequence encoding a polypeptide comprising a functional portion of a TCR, and wherein the functional portion has antigenic specificity for human papillomavirus (HPV) 16 E7 11-19 and comprises an alpha chain complementarity determining region (CDR) 1 amino acid sequence of SEQ ID NO: 3, an alpha chain CDR2 amino acid sequence of SEQ ID NO: 4, an alpha chain CDR3 amino acid sequence of SEQ ID NO: 5, a beta chain CDR1 amino acid sequence of SEQ ID NO: 6, a beta chain CDR2 amino acid sequence of SEQ ID NO: 7, and a beta chain CDR3 amino acid sequence of SEQ ID NO: 8.

11 . The method of claim 10 , wherein the functional portion comprises the amino acid sequence of:

(a) SEQ ID NO: 9;

(b) SEQ ID NO: 10;

(c) SEQ ID NOs: 9 and 10;

(d) (i) SEQ ID NOs: 9 and 24; (ii) SEQ ID NOs: 9 and 17; (iii) SEQ ID NO: 9 and 16; (iv) SEQ ID NO: 10 and 18; or (v) any one of SEQ ID NOs: 12, 13, 20, 22, 26, 27, 29 and 30;

(e) SEQ ID NOs: 12 and 13;

(f) SEQ ID NOs: 20 and 22;

(g) SEQ ID NOs: 26 and 27;

(h) SEQ ID NOs: 9, 24, and 27;

(i) SEQ ID NOs: 9, 17, and 20; or

(j) SEQ ID NOs: 9, 10, 16, and 18.

12 . The method of claim 10 , wherein the functional portion further comprises the amino acid sequences of:

(a) SEQ ID NO: 16, wherein

(i) X at position 48 is Thr or Cys;

(ii) X at position 112 is Ser, Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 114 is Met, Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp; and

(iv) X at position 115 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp; and

(b) SEQ ID NO: 18, wherein X at position 56 is Ser or Cys.

13 . The method of claim 10 , wherein the functional portion further comprises the amino acid sequences of:

(a) any one of SEQ ID NOs: 14, 17, 21, 24, and 25; and

(b) any one of SEQ ID NOs: 15, 19, and 23.

14 . The method of claim 10 , wherein the recombinant expression vector is a viral vector.

15 . The method of claim 10 , wherein the recombinant expression vector is a retroviral vector.

16 . A method of producing an engineered population of human cells, the method comprising:

introducing a recombinant expression vector to an isolated population of human cells, wherein the recombinant expression vector comprises a nucleotide sequence encoding a protein having antigenic specificity for human papillomavirus (HPV) 16 E7 11-19 and comprising a first polypeptide chain comprising an alpha chain complementarity determining region (CDR) 1 amino acid sequence of SEQ ID NO: 3, an alpha chain CDR2 amino acid sequence of SEQ ID NO: 4, and an alpha chain CDR3 amino acid sequence of SEQ ID NO: 5 and a second polypeptide chain comprising a beta chain CDR1 amino acid sequence of SEQ ID NO: 6, a beta chain CDR2 amino acid sequence of SEQ ID NO: 7, and a beta chain CDR3 amino acid sequence of SEQ ID NO: 8.

17 . The method of claim 16 , wherein:

the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 9 and

the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 10, wherein X at position 2 of SEQ ID NO: 10 is Ala or Gly.

18 . The method of claim 16 , wherein:

the first polypeptide chain further comprises the amino acid sequence of SEQ ID NO: 16, wherein:

(i) X at position 48 is Thr or Cys;

(ii) X at position 112 is Ser, Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 114 is Met, Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp; and

(iv) X at position 115 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp; and

the second polypeptide chain further comprises the amino acid sequence of SEQ ID NO: 18, wherein X at position 56 is Ser or Cys.

19 . The method of claim 16 , wherein:

the first polypeptide chain further comprises the amino acid sequence of any one of SEQ ID NOs: 14, 17, 21, 24, and 25; and

the first polypeptide chain further comprises the amino acid sequence of any one of any one of SEQ ID NOs: 15, 19, and 23.

20 . The method of claim 16 , wherein:

the first polypeptide chain comprises the amino acid sequence of (i) SEQ ID NO: 12, (ii) SEQ ID NO: 22, (iii) SEQ ID NO: 26, (iv) SEQ ID NO: 9 and 16, (v) SEQ ID NO: 9 and 17, or (vi) SEQ ID NO: 9 and 24 and

the second polypeptide chain comprises the amino acid sequence of (i) SEQ ID NO: 10 and 18 or (ii) any one of SEQ ID NOs: 13, 20, and 27.

Continuity (5)
Continuation 17101360 · Nov 23, 2020
Continuation 16205631 · Nov 30, 2018
Division 15313673
Provisional Application 62004335 · May 29, 2014
Related Publication 20220372103A1 · Nov 24, 2022
References Cited (65)
US 5087616A · Myers et al. · 1992 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5449752A · Fujii et al. · 1995 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5639641A · Pedersen et al. · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5714352A · Jakobobits et al. · 1998 [cited by applicant]
US 6265150B1 · Terstappen et al. · 2001 [cited by applicant]
US 8034334B2 · Dudley et al. · 2011 [cited by applicant]
US 8383099B2 · Dudley et al. · 2013 [cited by applicant]
US 10174098B2 · Hinrichs et al. · 2019 [cited by applicant]
US 10870687B2 · Hinrichs et al. · 2020 [cited by applicant]
US 20020197266A1 · Debinski · 2002 [cited by applicant]
US 20100189742A1 · Van Der Burg et al. · 2010 [cited by applicant]
US 20120244133A1 · Rosenberg et al. · 2012 [cited by applicant]
EP 0239400B1 · 1994 [cited by applicant]
GB 2188638A · 1987 [cited by applicant]
JP 2013505734A · 2013 [cited by applicant]
WO WO2006103429A2 · 2006 [cited by applicant]
WO WO2007131092A2 · 2007 [cited by applicant]
WO WO2011039508A2 · 2011 [cited by applicant]
WO WO2015009606A1 · 2015 [cited by applicant]
Clambrey et al (Journal of Molecular Medicine, 2014, vol. 92, pp. 733-741) (Year: 2014). [cited by examiner]
Tsukahara et al (Biochemical and Biophysical Research Communications, 2013, vol. 438, pp. 84-89) (Year: 2013). [cited by examiner]
Tamada et al (Clinical Cancer Research, 2012, pp. OF1-OF10) (Year: 2012). [cited by examiner]
Choi et al., “Synthesis and Assembly of a Cholera Toxin B Subunit-Rotavirus VP7 Fusion Protein in Transgenic Potato,” [cited by applicant]
Cohen et al., “Enhanced Antitumor Activity of T Cells Engineered to Express T-Cell Receptors with a Second Disulfide Bond,” [cited by applicant]
Dudley et al., “Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients,” [cited by applicant]
European Patent Office, Extended European Search Report in European Application No. 19217074.4, mailed Jul. 2, 2020. [cited by applicant]
Ferradini et al., “Studies on the human T cell receptor alpha/beta variable region genes, Part II,” [cited by applicant]
Haga-Friedman et al., “Incorporation of Transmembrane Hydrophobic Mutations in the TCR Enhance Its Surface Expression and T Cell Functional Avidity,” [cited by applicant]
Haskard et al., “The Production of Human Monoclonal Autoantibodies from Patients with Rheumatoid Arthritis by the EBV-Hybridoma Technique,” [cited by applicant]
Hinrichs et al., “HPV-targeted tumor-infiltrating lymphocytes for cervical cancer,” Abstract, ASCO Annual Meeting May 14, 2014. [cited by applicant]
Hudecz “Synthesis of Peptide Bioconjugates,” [cited by applicant]
Huse et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,” [cited by applicant]
International Bureau, International Search Report in International Patent Application No. PCT/US2015/033129, mailed Aug. 27, 2015. [cited by applicant]
International Bureau, Written Opinion in International Patent Application No. PCT/US2015/033129, mailed Aug. 27, 2015. [cited by applicant]
Keskin et al., “Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens,” [cited by applicant]
Kirin et al., “Amino Acid and Peptide Bioconjugates of Copper(II) and Zinc(II) Complexes with a Modified N,N-Bis(2-picolyl)amine Ligand,” [cited by applicant]
Köhler et al., “Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion,” [cited by applicant]
Lyons et al., “T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells,” [cited by applicant]
Meydan et al., “Prediction of peptides binding to MHC class I and II alleles by temporal motif mining,” [cited by applicant]
Nilges et al., “Human Papillomavirus Type 16 E7 Peptide-Directed CD8+ T Cells from Patients with Cervical Cancer are Cross-Reactive with the Coronavirus NS2 Protein,” [cited by applicant]
Pedersen et al., “Comparison of Surface Accessible Residues in Human and Murine Immunoglobulin Fv Domains: Implication for Humanization of Munrine Antibodies,” [cited by applicant]
Reiter et al., “Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv,” [cited by applicant]
Riddell et al., “The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells,” [cited by applicant]
Riemer et al., “A Conserved E7-derived Cytotoxic T Lymphocyte Epitope Expressed on Human Papillomavirus 16-transformed HLA-A2 + Epithelial Cancers,” [cited by applicant]
Roder et al., “The EBV-Hybridoma Technique,” [cited by applicant]
Roman-Roman et al., “Studies on the human T cell receptor alpha/beta variable region genes, Part I,” [cited by applicant]
Scholten et al., “Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer,” [cited by applicant]
Scholten et al., “Promiscuous behavior of HPV16E6 specific T cell expression in TCR transgenic T cells, which can be restored in part by genetic modification,” [cited by applicant]
Scholten et al., “Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer,” [cited by applicant]
“TRA T-cell receptor alpha locus [ [cited by applicant]
“TRB T cell receptor beta locus [ [cited by applicant]
Wadwa et al., “Receptor Mediated Glycotargeting,” [cited by applicant]
Youde et al., “Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line,” [cited by applicant]
Foy et al., “Non-viral precision T cell receptor replacement for personalized cell therapy”, Nature, 615: 687-696 (2023). [cited by applicant]
Jin et al., “Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model”, JCI Insight, 3(8): e99488, 12 pages (2018) and Supplementary Material (2 pages). [cited by applicant]
Jin et al., “Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules”, J Transl Med 16: 13, 13 pages (2018). [cited by applicant]
Nagarsheth et al., “TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers”, Nat Med, 27(3) 419-425 (2021). [cited by applicant]
Peng et al., “Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity”, Gene Ther, 16(8): 1042-1049 (2009). [cited by applicant]
Ramachandran et al., “Systemic and local immunity following adoptive transfer of NY-ESO-1 Spear T cells in synovial sarcoma”, Journal for ImmunoTherapy of Cancer, 7:276, 14 pages (2019). [cited by applicant]
Mensali et al., “NK cells specifically TCR-dressed to kill cancer cells”, EBioMedicine, 40: 106-117 (2019). [cited by applicant]